Prazer Therapeutics
PrivateLast Round
Series B
Apr 1, 2025
Est. Valuation
$79.1M
Total Funding Raised
$42.1M
Company Overview
Prazer Therapeutics is a biotechnology company developing innovative therapeutics for various intractable diseases using its proprietary targeted protein degradation (TPD) platform called SPiDEM.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prazer Therapeutics Comparables
Compare Prazer Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pin Therapeutics | 90% | |
| AUTOTAC Bio | 88% | |
| Amphista Therapeutics | 87% |
Prazer Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 1, 2025 | ||||
| Series A | Mar 8, 2021 | ||||
| Series A | Dec 23, 2020 |
Key People
Founding team and executive leadership
Prazer Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| K2 Investment Partners | Series B |
| Smilegate Investment | Series B, Series A |
| Premier Partners | Series B |
| QUAD Investment Management | Series B |
| Company K Partners | Series B, Series A |
| Kiwoom Investment | Series B, Series A |
| Mirae Asset Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 27, 2026
Grew 19% QoQ, from 27 to 32 employees.
- Apr 26, 2026
Grew 32% QoQ from 19 to 25 employees.
Prazer Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Prazer Therapeutics's valuation, stock price, and market status.
Is Prazer Therapeutics a public or private company?
Prazer Therapeutics is a private company.
What is the current stock price of Prazer Therapeutics?
Prazer Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Prazer Therapeutics worth (valuation)?
Valuation information for Prazer Therapeutics is not publicly available.
Can I buy Prazer Therapeutics stock?
Prazer Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Prazer Therapeutics's last funding round?
Prazer Therapeutics's most recent funding round was Series B on April 2, 2025.
Who are the main investors in Prazer Therapeutics?
Key investors in Prazer Therapeutics include Johnson & Johnson Innovation - JJDC, Inc..
Will Prazer Therapeutics IPO soon?
No public IPO plans have been announced for Prazer Therapeutics.
How can I track Prazer Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Prazer Therapeutics's secondary market activity and sign up for updates.